Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
Vivalis and Innate Pharma sign a collaboration and commercial license agreement
January 21, 2009
Vivalis and Innate Pharma sign a collaboration and commercial license agreement to develop Innate's novel monoclonal antibody, to be manufactured with Vivalis' EB66® platform, for rare cutaneous cancers.
| Download Area |
|---|
| PR in english |
| CP en français |